Notably, there was an increase in the frequencies of NKG2D+TIGIT− Vδ1 cells and NKG2D+Foxp3− Vδ2 cells in AML patients who achieved CR after chemotherapy (n = 6), which informed that these two subsets were intimately correlated with better outcomes (Figure 4D). This evidence concerns the gene FOXP3 and acute myeloid leukemia.